Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials - Wikidata - wikimedia - TriplyDB

Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials

Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials

http://www.wikidata.org/entity/Q36083337

about

HIV-1 prophylactic vaccines: state of the art Harnessing the protective potential of HIV-1 neutralizing antibodies Recent update in HIV vaccine development Contrasting Adult and Infant Immune Responses to HIV Infection and Vaccination Immune correlates of vaccine protection against HIV-1 acquisition HIV-1 neutralizing antibodies: understanding nature's pathways Neutralization-Enhancing RF Antibodies for HIV Vaccines HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design Mucosal B Cells Are Associated with Delayed SIV Acquisition in Vaccinated Female but Not Male Rhesus Macaques Following SIVmac251 Rectal Challenge Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques Molecular evolution of broadly neutralizing Llama antibodies to the CD4-binding site of HIV-1 Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2 Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies A Multiplex Microsphere-Based Immunoassay Increases the Sensitivity of SIV-Specific Antibody Detection in Serum Samples and Mucosal Specimens Collected from Rhesus Macaques Infected with SIVmac239 Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector Impact of HIV-1 backbone on neutralization sensitivity: neutralization profiles of heterologous envelope glycoproteins expressed in native subtype C and CRF01_AE backbone Monoclonal antibodies to the V2 domain of MN-rgp120: fine mapping of epitopes and inhibition of α4β7 binding HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development Aggregate complexes of HIV-1 induced by multimeric antibodies.CD8(+) T-cell effector function and transcriptional regulation during HIV pathogenesis Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy.HIV-1 vaccines: challenges and new perspectives Novel directions in HIV-1 vaccines revealed from clinical trials Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1.Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection.Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates.CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies Enhanced immunogenicity of an HIV-1 DNA vaccine delivered with electroporation via combined intramuscular and intradermal routes Which Antibody Functions are Important for an HIV Vaccine?Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge.Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.HIV-1 envelope proteins and V1/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1 Boosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein.Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination.Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.

P2860

Q26740042-23C8D248-0B59-4313-90A2-293840EC3313 Q26766153-3F3D86D9-81A6-4970-ACB3-9573F00ADD8F Q26766628-1E46275B-D62F-4067-82D2-C2D0C5793CD1 Q26776518-B957CDEA-841E-4D91-867D-A38363158978 Q26778573-34FBB5F9-6F0D-45CC-B6DD-956201B84B75 Q27000480-81D62140-0BE4-4E49-830F-85E8BCCE4483 Q27002322-A141BEA1-E1D4-4C2C-85AD-A183FBE112B2 Q27022055-9D3774D2-7808-48D9-9F84-2658B9429402 Q27318151-AF259FD7-3C6A-46B6-A1DD-95940D41CC57 Q27318508-B5385001-32E9-4BED-9876-FB22F7DDFE4D Q27322403-84321CAB-99F7-405F-B6A7-408E52B66713 Q27644501-3A58FD81-CC0B-4A85-B331-54C4B3861D4D Q27675879-5E40A166-DB59-4677-9AC5-094502E61A5A Q27681806-6A6E29AC-021A-4ED9-BE84-ECBB28C363C6 Q28299280-FBABF025-1A03-4EAE-98AE-21315C9435A6 Q28383579-3BF7197E-AF47-47A6-93C1-CF8875EFD9F0 Q28533970-8F619A3D-7CF8-467C-9902-6E92688A8F11 Q28535477-32BAFBC2-00E9-4DE1-B2F7-FA48988B857F Q28728517-C6B735F2-A084-44A5-B645-FC39257881DA Q30355260-BC63F067-1C17-4EF8-A569-19734AA39766 Q30428633-5DF8C479-F304-4D78-AEAE-DF6EE477650E Q30432007-73E839B5-732E-4D8D-AA13-029E3E111BF6 Q31138173-07C232C3-B747-4088-9EFF-49A7218A529E Q33577972-F61AAF89-575C-478A-B9DC-46DF6BA1DFA5 Q33645528-C254C262-5B32-4017-86AF-AF245465F41F Q33693391-D22C1F04-534D-4C74-9F94-8851851AEA58 Q33702217-58734191-DB62-4D6E-8F94-8FE0E2EB318A Q33712296-44783BCA-570C-4ECD-997E-89713AD25B17 Q33742529-92AE271C-62BD-4360-A731-AE746BCDAFCD Q33743734-4A658704-5CCE-4FE2-82AD-94FCF9A82C66 Q33743758-63CC3F6D-2881-449A-AB45-0E179D5BC001 Q33772637-E68F4822-EC50-4878-94A9-3B87074C08A9 Q33804531-CD4A15C4-A097-43F4-B2F8-17FBB79DDD1F Q33813145-3413804A-4F81-4D21-BFE4-35B000F505EB Q33874253-9E64FD73-2C2F-4C3B-A978-14CA980A2EDE Q33947008-1FAAFB7B-35EF-4914-8D69-57BB7366B9C1 Q33955745-D670FC7B-4E41-413E-B5B0-95925D964329 Q33977866-69EE5E04-CC95-46A5-A5CE-0FED7903FE52 Q34057711-93806B0E-2EDD-46C2-B5DF-22CB9CD0064D Q34057942-D4A660FD-72BA-4CE1-80E7-AE067BBE0736

P2860

Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials

http://www.wikidata.org/entity/Q36083337

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Magnitude and breadth of the n ...... HIV-1 vaccine efficacy trials

@ast

Magnitude and breadth of the n ...... HIV-1 vaccine efficacy trials

@en

type

label

Magnitude and breadth of the n ...... HIV-1 vaccine efficacy trials

@ast

Magnitude and breadth of the n ...... HIV-1 vaccine efficacy trials

@en

prefLabel

Magnitude and breadth of the n ...... HIV-1 vaccine efficacy trials

@ast

Magnitude and breadth of the n ...... HIV-1 vaccine efficacy trials

@en

P1433

Q36083337-D1EC7D4A-E77E-40CA-ADDC-B5B32104BDB8

P1476

Q36083337-78B7DBCE-6AB8-4A6D-BF9B-33A091D431F6

P2093

Q36083337-07A5D156-3DA7-4FF4-AF73-78FD9E0E5D18

Q36083337-13C29D47-7C1A-410F-A1FF-D1271DA59933

Q36083337-20E7D797-0E54-48B8-8409-636D03803BFF

Q36083337-2B28B96E-67CA-4D5A-8F02-0A7E65BEFD13

Q36083337-327B7C69-BDEF-4915-A591-BB3C53D99226

Q36083337-3457D853-1439-4350-AE78-52FE033C4CBE

Q36083337-349061EB-D056-4FAF-B7D9-34A47F14FB77

Q36083337-3AB33B8E-92E3-4BF9-9FDD-78227EBDE12E

Q36083337-59F05434-0AD8-42CF-9364-4CF441C123CB

Q36083337-5EE67487-0781-4A80-B69C-AAACE7243CC4

P2860

Q36083337-0477CEF6-7AD9-4539-9F87-8C1EC9222861

Q36083337-09809A02-E083-4473-A0F5-7C2161319279

Q36083337-0B7D203B-AC05-454B-BB10-45235B57C0C6

Q36083337-124F0D70-4E21-4E1E-A3D9-78F22C5E344A

Q36083337-14DA8B47-BC4C-493E-8A0A-E1A3B3547444

Q36083337-1878D77F-4698-4410-BD97-8B02934483BF

Q36083337-1AA9E5D6-A01E-4728-A062-8F14A1F7863E

Q36083337-21EB91B7-2908-443F-8647-2BFAA635F95E

Q36083337-264CAA9F-74FA-428C-B40F-19DE990B8F8B

Q36083337-2AC5055E-A0DE-448D-AFD0-37C063935B0F

P304

Q36083337-A4E9CE01-3CBE-4B75-A534-8E2400AC5F17

P31

Q36083337-FC9A72AF-CC13-4F2A-A375-7DAC6D48A80C

P356

Q36083337-128645D7-37CE-4305-B265-1C68D980D89A

P407

Q36083337-D0C7A9D5-80FA-4F0E-83AA-F27EC15F9154

P433

Q36083337-5CE93BD0-2FC6-4F8A-8401-E2846D40A4ED

P478

Q36083337-E1125498-3894-40BF-AB2F-2F89F7FCB2B8

P50

Q36083337-15576A45-12FF-4B68-8124-545BB16898FD

Q36083337-15718122-D5A6-4C76-90D9-9B7DC80378E8

Q36083337-18976F8B-FB6B-4F40-A8CA-01A0CF63DD0C

Q36083337-1A63C0EF-466D-4E54-8C5A-18A0F1B3E60F

Q36083337-35EE34AA-C94A-4C3A-9DD0-EC75336DA555

Q36083337-4CBE34C0-3DC9-4A48-845D-FB1F2144DBB1

Q36083337-65E0EB3F-2075-4603-8FC6-81EC49D95554

Q36083337-917AEC0C-515D-465F-BC68-57D0BAD39106

Q36083337-CA7667C5-8997-4EDF-97F9-716D31EF1A67

P577

Q36083337-F16871CA-4774-487F-922D-915848D25F73

P5875

Q36083337-6505E479-5B15-4A6C-9958-D0627AAEDC95

P698

Q36083337-41E095BC-F683-4506-A7A2-4F728437495C

P921

Q36083337-40CF840A-6103-4D96-B0FD-E9E731F1EC38

P932

Q36083337-F0DC599E-051F-4F58-8CD7-E97340E51F70

P356

P1433

The Journal of Infectious Diseases

P1476

Magnitude and breadth of the n ...... HIV-1 vaccine efficacy trials

@en

P2093

Agnes Laurence-Chenine

http://www.w3.org/2001/XMLSchema#string

Carter Lee

http://www.w3.org/2001/XMLSchema#string

Celia C LaBranche

http://www.w3.org/2001/XMLSchema#string

Charla Andrews

http://www.w3.org/2001/XMLSchema#string

Chitraporn Karnasuta

http://www.w3.org/2001/XMLSchema#string

Christina Ochsenbauer

http://www.w3.org/2001/XMLSchema#string

Donald Francis

http://www.w3.org/2001/XMLSchema#string

Faruk Sinangil

http://www.w3.org/2001/XMLSchema#string

Haili Tang

http://www.w3.org/2001/XMLSchema#string

Hasan Ahmed

http://www.w3.org/2001/XMLSchema#string

P2860

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

Rapid cloning of high-affinity human monoclonal antibodies against influenza virus

Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure

H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

Antibody neutralization and escape by HIV-1

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

P304

431-441

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/INFDIS/JIS367

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

206

http://www.w3.org/2001/XMLSchema#string

P50

David C Montefiori

Eric Sanders-Buell

Sodsai Tovanabutra

Victoria R Polonis

Supachai Rerks-Ngarm

P577

2012-05-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225064272

http://www.w3.org/2001/XMLSchema#string

P698

22634875

http://www.w3.org/2001/XMLSchema#string

P921

P932

3392187

http://www.w3.org/2001/XMLSchema#string